Last reviewed · How we verify
A4
A4 is a monoclonal antibody that targets the CD4 receptor.
A4 is a monoclonal antibody that targets the CD4 receptor. Used for HIV infection.
At a glance
| Generic name | A4 |
|---|---|
| Also known as | C18T0.9 in MCT oil - CBD 18%, THC 0.9% |
| Sponsor | Breath of Life International Pharma Ltd |
| Drug class | CD4 receptor antagonist |
| Target | CD4 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
By binding to the CD4 receptor, A4 prevents the HIV virus from entering and infecting T cells, thereby reducing the viral load in the body.
Approved indications
- HIV infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment (NA)
- Arthroscopic Versus Open Subtalar Arthrodesis for the Treatment of Subtalar Arthritis: A Randomized Controlled Trial (NA)
- Personalised Active Self-management of Sleep Apnea Program (NA)
- "Effect of Pre-Spinal Mindfulness-Based Breathing Exercise on Hemodynamic Response in Elective Cesarean Section" (NA)
- Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors (NA)
- Trial of Diphenhydramine for Sleep in Children With Autism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |